Methods of Hybridoma Formation

1. Front Matter

   Pages i-xxv

   PDF

2. Current Methodologies in Hybridoma Formation

   • Arie H. Bartal, Yashar Hirshaut

   Pages 1-40

3. Retroviruses and Hybridoma Formation

   • Arie H. Bartal, Yashar Hirshaut

   Pages 41-61

4. Mechanisms of Cell Fusion and Selection in the Generation of Hybridomas

   • Jerry W. Shay

   Pages 63-75

5. Chemically Mediated Cell Fusion

   • Robert J. Klebe, Kevin L. Bentley

   Pages 77-96

6. Electrofusion of Cells

   • U. Zimmermann

   Pages 97-149

7. Enhancement of Hybridoma Formation

   • Arie H. Bartal, Yashar Hirshaut

   Pages 151-161

8. Modification of HAT Medium and Hybridoma Formation

   • Arie H. Bartal, Carl Feit, Yashar Hirshaut

   Pages 163-179

9. Culture Methods for the Selection and Isolation of Stable Antibody-Producing Murine Hybridomas

   • R. Thomas Taggart

   Pages 181-194

10. Selection of Growth Factors and Myelomas To Enhance Monoclonal Antibody-Producing Hybridoma Formation

    • Janet H. Ransom, Martin V. Haspel

    Pages 195-208

11. Proliferation and Immune Secretion of B-Cell Hybridomas

    • Regine J. J. M. Westerwoudt

    Pages 209-230

12. Statistical Assessment of Hybridoma Monoclonality After Subcloning by the Limiting Dilution Technique

    • Hilary A. Coller, Barry S. Coller

    Pages 231-236

13. In Vitro Immunization for the Generation of Hybridomas Using Serum-Free Medium

    • Frederick J. Darfler

    Pages 237-248

14. Intrasplenic Immunization for the Production of Monoclonal Antibodies

    • M. Spitz, Lidia Spitz

    Pages 249-255

15. Use of Heteromyelomas in the Enhancement of Human Monoclonal Antibody Production

    • Nelson N. H. Teng, Marcia Bieber

    Pages 257-271

16. Human Hybridomas

    • Danuta Kozbor, Carlo M. Croce

    Pages 273-298

17. Antibody-Secreting Human-Human Hybridomas

    • Lennart Olsson

    Pages 299-316

18. Interspecific Hybridomas

    • John A. Sogn

    Pages 317-335

19. Rat-Rat Hybridoma Formation and Rat Monoclonal Antibodies

    • Hervé Bazin

    Pages 337-378

20. Generation of Mutant Monoclonal Antibodies

    • Gad Spira, Hector L. Aguila, Ellyn Fischberg, Matthew D. Scharff

    Pages 379-397

Laymen often consider modern laboratory research to be based on an endless array of sophisticated technologies whose complex capabilities are as important to the outcome of any project as the inventiveness and creativity of the scientists who employ them. Scientists at times may share this point of view until they are con­ fronted by unexpected findings that demand new approaches, and they discover that yesterday's "sophisticated tools" are today's "blunt instruments." This experience provides a more sobering view of the current state of our scientific methods. It also serves as an impetus for the further development of technology that prepares us for the next stage of advance. Immunologists were confronted by such a technological crises in the late 1970s when they finally were forced to admit that poly­ clonal antibodies, although quite sensitive reagents, were not spe­ cific enough to answer many of the questions then confronting virologists and tumor biologists. The answer to the need for specific­ ity came with the development of monoclonal antibody technology. In the last ten years there have been considerable advances in monoclonal antibody techniques. Today these reagents are much more versatile than they were initially and can be applied to a broad range of problems. Still, most workers who are using these anti­ bodies are convinced that their potential is far from exhausted, and that at least in some fields we are currently in the early stages of learning how to use them properly.

• DNA
• Expression
• Interferon
• Macrophages
• Polysaccharide
• Promoter
• Termination
• Transport
• Viruses
• Vivo
• biosynthesis
• cell lines
• cloning
• genes
• splenocytes

• Biotherapeutics, Inc., Franklin, USA

  Arie H. Bartal

• Hybridoma Laboratory, Northern Israel Oncology Center, Rambam Medical Center, Haifa, Israel

  Arie H. Bartal

• Sloan-Kettering Cancer Center, New York, USA

  Yashar Hirshaut

Policies and ethics